Chinese Liver Cancer Clinical Survey

Primary Liver Cancer Clinical Trial

— CLCS  

Official title:

Chinese Liver Cancer Clinical Survey

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03161925
• Other study ID #: INW161116CLCS
• Status: Active, not recruiting
• Phase: N/A
• First received: May 19, 2017
• Last updated: May 19, 2017
• Start date: November 28, 2016
• Est. completion date: August 31, 2017

Study information

• Verified date: May 2017
• Source: Beijing Insight Science & Technology Co. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch "Chinese Liver Cancer clinical Survey" project in cancer specialized hospitals and large general hospitals and to explore the best clinical pathway of PLC multidisciplinary consultation.

Description:

Primary liver cancer (PLC) is one of the most common malignant tumors of digestive system and also a serious threat to the health and safety of Chinese people, and has caused serious economic burden to the country. Research purposes: To understand the clinical characteristics of patients with primary liver cancer (PLC) in China; To investigate the etiology and pathogenesis of PLC in China; To understand the current status of clinical treatment of PLC in China, and to analyze the gaps among these conditions and domestic treatment guidelines, industry consensus, the international treatment guidelines; To understand the different treatment options and its clinical outcomes, and to explore the best treatment options; To explore the best clinical pathway of PLC multidisciplinary consultation; To provide the basis for the development of clinical guidelines for PLC in China.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5000
• Est. completion date: August 31, 2017
• Est. primary completion date: August 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis of PLC after January 1,2012;

• First treatment and efficacy evaluation.

Exclusion Criteria:

• Complicated with another primary malignant tumor and secondary liver cancer.

Related Conditions & MeSH terms

• Liver Neoplasms
• Primary Liver Cancer

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Insight Science & Technology Co. Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Overall survival	5 years